BACKGROUND: Homocysteinemia has been associated with oncogenic risk. This study was designed to investigate the homocysteine (Hcy) genotype/phenotype interactions together with the inflammatory and nutritional status of cancer patients. PATIENTS AND METHODS: The Hcy levels were analyzed in 47 cancer patients in association with methylenetetrahydrofolate reductase (MTHFR) polymorphisms, folate and inflammatory markers. RESULTS: The MTHFR C677T and A1298C genotype distributions did not differ from those predicted by the Hardy-Weinberg distribution. Conversely, the Hcy levels were higher in the cancer patients (p=0.04), who were also characterized by low-grade inflammation. The Hcy levels correlated with the interleukin-6 (IL-6) (p=0.001), tumor necrosis factor-alpha (TNF-alpha) (p=0.042) and folate (p<0.0001) levels of the patients. Multivariate analysis showed that TNF-alpha (p=0.014) and folate (p=0.019) were independent predictors of elevated Hcy levels in the cancer patients. CONCLUSION: The MTHFR polymorphisms do not significantly contribute to tHcy (total Hcy) levels in cancer patients, and cancer-related inflammation may be associated with elevated tHcy levels, possibly involving a TNF-alpha mediated pathway.
BACKGROUND:Homocysteinemia has been associated with oncogenic risk. This study was designed to investigate the homocysteine (Hcy) genotype/phenotype interactions together with the inflammatory and nutritional status of cancerpatients. PATIENTS AND METHODS: The Hcy levels were analyzed in 47 cancerpatients in association with methylenetetrahydrofolate reductase (MTHFR) polymorphisms, folate and inflammatory markers. RESULTS: The MTHFRC677T and A1298C genotype distributions did not differ from those predicted by the Hardy-Weinberg distribution. Conversely, the Hcy levels were higher in the cancerpatients (p=0.04), who were also characterized by low-grade inflammation. The Hcy levels correlated with the interleukin-6 (IL-6) (p=0.001), tumor necrosis factor-alpha (TNF-alpha) (p=0.042) and folate (p<0.0001) levels of the patients. Multivariate analysis showed that TNF-alpha (p=0.014) and folate (p=0.019) were independent predictors of elevated Hcy levels in the cancerpatients. CONCLUSION: The MTHFR polymorphisms do not significantly contribute to tHcy (total Hcy) levels in cancerpatients, and cancer-related inflammation may be associated with elevated tHcy levels, possibly involving a TNF-alpha mediated pathway.
Authors: Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan Journal: J Transl Med Date: 2011-03-04 Impact factor: 5.531
Authors: Jose D Santotoribio; Consuelo Cañavate-Solano; Angela Garcia-de la Torre; Luis Del Valle-Vazquez; Francisco Arce-Matute; Juan F Cuadros-Muñoz; Maria J Sanchez del Pino; Manuel J Bandez-Ruiz; Carmen Piñuela-Rojas; Santiago Perez-Ramos Journal: Tumour Biol Date: 2015-05-09
Authors: Viktor Komlósi; Erika Hitre; Eva Pap; Vilmos Adleff; Andrea Réti; Eva Székely; Anna Bíró; Péter Rudnai; Bernadette Schoket; Judit Müller; Béla Tóth; Szabolcs Ottó; Miklós Kásler; Judit Kralovánszky; Barna Budai Journal: BMC Cancer Date: 2010-10-04 Impact factor: 4.430
Authors: Xiayu Wu; Tianning Zou; Neng Cao; Juan Ni; Weijiang Xu; Tao Zhou; Xu Wang Journal: Hered Cancer Clin Pract Date: 2014-02-21 Impact factor: 2.857